Summit Therapeutics hits possible snag on lung cancer drug seen as blockbuster
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Drugs have been the standard migraine treatment for decades. The severe headaches, nausea, and other problems associated with this common ...
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to ...
Takeda Pharmaceutical is expanding its prospects in hematology with a deal for rights to a drug advancing to pivotal testing ...
Credit: PD Neurotechnology The use of PD Neurotechnology's pioneering telemonitoring device to assess Parkinson's Disease (PD) symptoms and inform medication ...
Credit: Pixabay/CC0 Public Domain Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics ...
Alector Therapeutics said Monday that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what ...
An ultra-rare enzyme deficiency that keeps infants from achieving proper muscle function among other developmental delays now has its first ...
Six months after launching with a mega-round of financing, Seaport Therapeutics has raised $225 million more to advance a lead ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.